Skip to content

A randomized, controlled, double-blind, multicenter, Sympathetic ganglion, high-voltage pulsed radiofrequency ablation of peripheral neuralgia in patients with diabetic foot

A randomized, controlled, double-blind, multicenter, Sympathetic ganglion, high-voltage pulsed radiofrequency ablation of peripheral neuralgia in patients with diabetic foot

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069525
Enrollment
Unknown
Registered
2023-03-20
Start date
2023-03-20
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes foot with moderate to severe pain in peripheral nerve of affected limb

Interventions

A group:Pulsed radiofrequency therapy, after two months of follow-up, they underwent sham surgery
B group:Sham surgery, after two months of follow-up, they underwent pulsed radiofrequency therapy

Sponsors

Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Subjects voluntarily participated in the study and signed the informed consent form; 2. The age is between 18 (inclusive) and 85 (inclusive), regardless of gender; 3. Body mass index (BMI) = 45; 4. Clinically diagnosed diabetes foot with moderate and severe pain in peripheral nerve of affected limb (defined as NRS score = 4), the course of disease lasts for more than 12 months, and has been treated with clinical routine standard drugs (mecobalamin a- Lipoic acid, sodium valproate, carbamazepine, gabapentin, etc.) symptoms still exist at least 6 months later; 5. Glycated hemoglobin<8%; 6. Not participating in the drug/medical device test within 3 months before the test;

Exclusion criteria

Exclusion criteria: 1. Patients with poor general conditions who cannot objectively describe symptoms or cooperate in completing the questionnaire score; 2. The skin of the affected limb has ulcerative redness or active inflammatory infection; 3. The affected limb has lesions such as blackening and gangrene of the toe skin; 4. Those suffering from severe respiratory and cardiovascular diseases, liver and kidney insufficiency, and malignant tumors; 5. Breast-feeding and pregnant women, or subjects with pregnancy plan within 1 month after the trial (also including male subjects); 6. The daily dose of opioids is more than 120mg; 7. People with allergic diseases and allergic constitution; 8. Have a history of drug abuse or drug addiction; 9. There are contraindications to pulsed radio frequency therapy;

Design outcomes

Primary

MeasureTime frame
Numerical scoring;Blood flow doppler;

Secondary

MeasureTime frame
European Quality of Life Scale;Skin temperature measurement;Toe oxygen saturation measurement;Anxiety and depression score;

Countries

China

Contacts

Public ContactKe Ma

Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine

marke72@163.com13361879260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026